![](/img/cover-not-exists.png)
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial
Dieci, M. V., Prat, A., Tagliafico, E., Paré, L., Ficarra, G., Bisagni, G., Piacentini, F., Generali, D. G., Conte, P., Guarneri, V.Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw262
Date:
August, 2016
File:
PDF, 218 KB
english, 2016